Regen Biopharma Inc (RGBPP) Stock Price & Analysis

Regen Biopharma Inc (RGBPP) fell 7.41% to USD 0 as of September 8, 2026 at 10:52 UTC, according to Nexqual real-time market data.

RGBPP last closed at USD 0; the session ranged USD 0–0 on volume of 85,183 shares. Market capitalization is —, with a 52-week range of USD 0–0.1 (OID). Source: Nexqual, September 8, 2026 at 10:52 UTC.

Key Statistics (as of September 8, 2026 at 10:52 UTC)

Technical Analysis (RGBPP)

Nexqual's technical model rates RGBPP "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 10:52 UTC.

From Regen Biopharma Inc's Latest SEC 10-K Filing (filed 2025-12-30)

Key Strengths & Strategy (as disclosed to the SEC)

• After testing in animals, an Investigational New Drug Application ("IND") must be filed with the FDA to obtain authorization for human testing.
• No action can be taken to market any therapeutic product in the United States until an appropriate New Drug Application ("NDA") or Biologic License Application ("BLA") or has been approved by the FDA.
• The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.   DiffronC: This drug is intended to use our proprietary siRNA in vivo to inhibit cancer growth and activate T cells.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:52 UTC. This page is informational and not investment advice.